Edward Tuddenham

List of Publications by Year
in descending order

236 papers	18,152 citations	16451 64 h-index	13379 130 g-index
239 all docs	239 docs citations	239 times ranked	10221 citing authors

#	Article	IF	Citations
1	Adenovirus-Associated Virus Vectorâ€“Mediated Gene Transfer in Hemophilia B. New England Journal of Medicine, 2011, 365, 2357-2365.	27.0	1,606
2	Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B. New England Journal of Medicine, 2014, 371, 1994-2004.	27.0	1,063
3	Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature, 2004, 427, 537-541.	27.8	1,039
4	The Hemophilias â€" From Royal Genes to Gene Therapy. New England Journal of Medicine, 2001, 344, 1773-1779.	27.0	936
5	Structure of human factor VIII. Nature, 1984, 312, 337-342.	27.8	869
6	Expression of active human factor VIII from recombinant DNA clones. Nature, 1984, 312, 330-337.	27.8	698
7	BIOPSY OF HUMAN PREIMPLANTATION EMBRYOS AND SEXING BY DNA AMPLIFICATION. Lancet, The, 1989, 333, 347-349.	13.7	428
8	Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood, 2006, 107, 2653-2661.	1.4	366
9	Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation. Thrombosis and Haemostasis, 1995, 74, 1402-1406.	3.4	283
10	Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nature Genetics, 2003, 34, 220-225.	21.4	282
11	Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature, 1985, 317, 726-729.	27.8	275
12	Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood, 2007, 109, 1414-1421.	1.4	246
13	Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene. Nature, 1985, 314, 738-740.	27.8	242
14	Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood, 2013, 121, 3335-3344.	1.4	236
15	Noninvasive prenatal diagnosis of hemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood, 2011, 117, 3684-3691.	1.4	232
16	Crystal structure of the extracellular region of human tissue factor. Nature, 1994, 370, 662-666.	27.8	230
17	A Molecular Model for the Triplicated A Domains of Human Factor VIII Based on the Crystal Structure of Human Ceruloplasmin. Blood, 1997, 89, 2413-2421.	1.4	214
18	The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Research, 1998, 26, 216-219.	14.5	208

#	Article	IF	Citations
19	Detection and sequence of mutations in the factor VIII gene of haemophiliacs Â. Nature, 1985, 315, 427-430.	27.8	206
20	A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nature Genetics, 1994, 6, 205-209.	21.4	202
21	High Prevalence of Elevated Factor VIII Levels in Patients Referred for Thrombophilia Screening: Role of Increased Synthesis and Relationship to the Acute Phase Reaction. Thrombosis and Haemostasis, 1997, 77, 0825-0828.	3.4	196
22	Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease. British Journal of Haematology, 1982, 52, 259-267.	2.5	178
23	Enhanced thrombin generation in patients with cirrhosisâ€induced coagulopathy. Journal of Thrombosis and Haemostasis, 2010, 8, 1994-2000.	3.8	170
24	Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood, 2011, 117, 798-807.	1.4	163
25	HLA Genotype of Patients with Severe Haemophilia A due to Intron 22 Inversion with and without Inhibitors of Factor VIII. Thrombosis and Haemostasis, 1997, 77, 238-242.	3.4	163
26	Factor VII deficiency and the FVII mutation database. Human Mutation, 2001, 17, 3-17.	2.5	159
27	Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure. American Heart Journal, 1994, 127, 607-612.	2.7	157
28	Environmental and genetic factors influencing inhibitor development. Seminars in Hematology, 2004, 41, 82-88.	3.4	147
29	Characterization of a murine homeo box gene, Hox-2.6, related to the Drosophila Deformed gene.. Genes and Development, 1988, 2, 1424-1438.	5.9	146
30	450 million years of hemostasis. Journal of Thrombosis and Haemostasis, 2003, 1, 1487-1494.	3.8	143
31	Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2Î± mutation. Blood, 2008, 112, 919-921.	1.4	143
32	An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. Journal of Thrombosis and Haemostasis, 2013, 11, 1329-1340.	3.8	138
33	Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies. Biochemistry, 1985, 24, 4294-4300.	2.5	137
34	A new polymorphism in the factor VIII gene for prenatal diagnosis of hemophilia A. Nucleic Acids Research, 1986, 14, 4535-4542.	14.5	137
35	Haemophilia A diagnosis by analysis of a hypervariable dinucleotide repeat within the factor VIII gene. Lancet, The, 1991, 338, 207-211.	13.7	133
36	Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy. Blood, 2004, 104, 2714-2721.	1.4	132

#	Article	IF	Citations
37	Haemophilia A: database of ncleotide substituttions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Research, 1991, 19, 4821-4833.	14.5	123
38	Molecular etiology of factor VIII deficiency in hemophilia A. Human Mutation, 1995, 5, 1-22.	2.5	123
39	Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII. Blood, 1984, 63, 31-41.	1.4	119
40	Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thrombosis and Haemostasis, 2005, 93, 23-26.	3.4	115
41	Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Research, 1994, 22, 3511-3533.	14.5	112
42	Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood, 2006, 107, 1903-1907.	1.4	111
43	Inherited Factor VII Deficiency: Molecular Genetics and Pathophysiology. Thrombosis and Haemostasis, 1997, 78, 151-160.	3.4	103
44	A CLINICALLY USEFUL DNA PROBE CLOSELY LINKED TO HAEMOPHILIA A. Lancet, The, 1984, 324, 6-8.	13.7	99
45	Desmopressin and bleeding time in patients with cirrhosis.. BMJ: British Medical Journal, 1985, 291, 1377-1381.	2.3	98
46	Complete Inhibition of Acute Humoral Rejection Using Regulated Expression of Membrane-tethered Anticoagulants on Xenograft Endothelium. American Journal of Transplantation, 2004, 4, 1958-1963.	4.7	93
47	Molecular analysis of the genotype-phenotype relationship in factor VII deficiency. Human Genetics, 2000, 107, 327-342.	3.8	92
48	A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood, 2005, 106, 542-549.	1.4	89
49	Molecular evolution of the vertebrate blood coagulation network. Thrombosis and Haemostasis, 2003, 89, 420-428.	3.4	88
50	Menorrhagia in Adolescents with Inherited Bleeding Disorders. Journal of Pediatric and Adolescent Gynecology, 2010, 23, 215-222.	0.7	86
51	Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. British Journal of Haematology, 1998, 100, 773-776.	2.5	84
52	Crystal Structure of Active Site-Inhibited Human Coagulation Factor VIIa (des-Gla). Journal of Structural Biology, 1999, 127, 213-223.	2.8	77
53	Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven^{Â®}] in elective orthopaedic surgery in haemophilic patients with inhibitors. Haemophilia, 2009, 15, 501-508.	2.1	77
54	Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer. Blood, 2018, 132, 491-491.	1.4	77

#	Article	IF	Citations
55	Haemostatic problems in liver disease.. Gut, 1986, 27, 339-349.	12.1	76
56	Thromboelastography, whole-blood haemostasis and recurrent miscarriage. Human Reproduction, 2003, 18, 2540-2543.	0.9	76
57	Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q). Biochemistry, 1994, 33, 14162-14169.	2.5	74
58	Haemophilia A diagnosis by simultaneous analysis of two variable dinucleotide tandem repeats within the factor VIII gene. British Journal of Haematology, 1994, 86, 804-809.	2.5	72
59	Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia, 2010, 16, 584-591.	2.1	71
60	Inherited Factor X Deficiency: Molecular Genetics and Pathophysiology. Thrombosis and Haemostasis, 1997, 78, 161-172.	3.4	71
61	A G â†' A substitution in an HNF I binding site in the human Î±-fetoprotein gene is associated with hereditary persistence of Î±-fetoprotein (HPAFP). Human Molecular Genetics, 1993, 2, 379-384.	2.9	70
62	Synthesis and Release of Factor VIII by Cultured Human Endothelial Cells. British Journal of Haematology, 1981, 47, 617-626.	2.5	67
63	Von Willebrand factor multimer patterns in von Willebrand's disease. British Journal of Haematology, 1983, 55, 493-507.	2.5	67
64	Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood, 2008, 111, 5592-5600.	1.4	63
65	Molecular defects in CRM+ factor VII deficiencies: modelling of missense mutations in the catalytic domain of FVII. British Journal of Haematology, 1994, 86, 610-618.	2.5	61
66	Epidemiology of coagulation disorders. Best Practice and Research: Clinical Haematology, 1992, 5, 383-439.	1.1	58
67	Characterization of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. British Journal of Haematology, 1995, 91, 458-464.	2.5	58
68	Coagulation and fibrosis in chronic liver disease. Gut, 2008, 57, 1722-1727.	12.1	58
69	Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood, 1996, 87, 4187-4196.	1.4	57
70	Localization of factor VIIIC: antigen in guinea-pig tissues and isolated liver cell fractions. British Journal of Haematology, 1984, 56, 535-543.	2.5	56
71	Homozygous protein C deficiency with delayed onset of symptoms at 7 to 10 months. Thrombosis Research, 1989, 53, 475-484.	1.7	55
72	The Factor VIII Mutation Database on the World Wide Web: The Haemophilia A Mutation, Search, Test and Resource Site HAMSTeRS Update (version 3.0). Nucleic Acids Research, 1997, 25, 128-132.	14.5	55

#	Article	IF	Citations
73	Science, medicine, and the future: Assessing thrombotic risk. BMJ: British Medical Journal, 1998, 317, 520-523.	2.3	55
74	Factor Xa and thrombin, but not factor VIIa, elicit specific cellular responses in dermal fibroblasts. Journal of Thrombosis and Haemostasis, 2003, 1, 1935-1944.	3.8	54
75	Prospects for gene therapy of haemophilia. Haemophilia, 2004, 10, 309-318.	2.1	54
76	Advances in Gene Therapy for Hemophilia. Human Gene Therapy, 2017, 28, 1004-1012.	2.7	54
77	Six point mutations that cause factor XI deficiency. Blood, 1995, 85, 1509-1516.	1.4	54
78	Inactivation of factor VIII by factor IXa. Biochemistry, 1992, 31, 2805-2812.	2.5	51
79	Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis. Blood, 2004, 103, 3381-3387.	1.4	50
80	Energetic Contributions and Topographical Organization of Ligand Binding Residues of Tissue Factor. Biochemistry, 1995, 34, 6310-6315.	2.5	49
81	Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium. Blood, 2004, 104, 1344-1349.	1.4	49
82	Coronary Thrombosis and the Platelet Glycoprotein IIIA Gene PLA2 Polymorphism. Thrombosis and Haemostasis, 1998, 80, 218-219.	3.4	48
83	Factor VIII - novel insights into form and function. British Journal of Haematology, 2002, 119, 323-331.	2.5	47
84	Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. British Journal of Haematology, 2003, 123, 496-501.	2.5	46
85	The genetic basis of inhibitor development in haemophilia A. Haemophilia, 1998, 4, 543-545.	2.1	45
86	AAV-mediated gene transfer in the perinatal period results in expression of FVII at levels that protect against fatal spontaneous hemorrhage. Blood, 2012, 119, 957-966.	1.4	44
87	Factor VIII gene mutations found by a comparative study of SSCP, DGGE and CMC and their analysis on a molecular model of factor VIII protein. Human Genetics, 1997, 101, 323-332.	3.8	43
88	REGULATED INHIBITION OF COAGULATION BY PORCINE ENDOTHELIAL CELLS EXPRESSING P-SELECTIN-TAGGED HIRUDIN AND TISSUE FACTOR PATHWAY INHIBITOR FUSION PROTEINS. Transplantation, 1999, 68, 832-839.	1.0	42
89	Solution structure of the major factor VIII binding region on von Willebrand factor. Blood, 2014, 123, 4143-4151.	1.4	41
90	Immunologic studies of factor VIII coagulant activity (VIII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C. Thrombosis Research, 1981, 21, 431-445.	1.7	40

#	Article	IF	Citations
91	A maximum likelihood estimate of the sex ratio of mutation rates in Haemophilia A. Human Genetics, 1983, 64, 156-159.	3.8	40
92	Identification of two novel mutations in non-Jewish factor XI deficiency. British Journal of Haematology, 1995, 90, 916-920.	2.5	40
93	Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thrombosis and Haemostasis, 2011, 106, 521-527.	3.4	39
94	Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia, 2012, 18, 241-245.	2.1	39
95	The Locus for Combined Factor V-Factor VIII Deficiency (F5F8D) Maps to 18q21, between D18S849 and D18S1103. American Journal of Human Genetics, 1997, 61, 143-150.	6.2	38
96	An immunoradiometric assay for human factor VIII/von Willebrand factor (VIII:vWF) using a monoclonal antibody that defines a functional epitope. British Journal of Haematology, 1985, 59, 565-577.	2.5	37
97	Purification and characterization of factor VIII 1,689-Cys: a nonfunctional cofactor occurring in a patient with severe hemophilia A. Blood, 1989, 73, 2117-2122.	1.4	37
98	Platelet membrane glycoprotein Ibalpha gene -5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis. British Heart Journal, 2002, 87, 70-74.	2.1	37
99	Live birth following the first mutation specific pre-implantation genetic diagnosis for haemophilia A. Thrombosis and Haemostasis, 2006, 95, 373-379.	3.4	37
100	GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant. Blood, 2018, 132, 489-489.	1.4	36
101	INHIBITION OF TISSUE FACTOR-DEPENDENT AND -INDEPENDENT COAGULATION BY CELL SURFACE EXPRESSION OF NOVEL ANTICOAGULANT FUSION PROTEINS. Transplantation, 1999, 67, 467-474.	1.0	35
102	ANTENATAL DIAGNOSIS AND CARRIER DETECTION OF HAEMOPHILIA A USING FACTOR VIII GENE PROBE. Lancet, The, 1985, 325, 1093-1094.	13.7	34
103	High-level production of human blood coagulation factors VII and XI using a new mammalian expression vector. Gene, 1994, 139, 275-279.	2.2	34
104	Novel, human cell lineâ€derived recombinant factor VIII (humanâ€cl rhFVIII; Nuwiq^{Â®}) in adults with severe haemophilia A: efficacy and safety. Haemophilia, 2016, 22, 225-231.	2.1	34
105	Efficient gene transfer into human umbilical vein endothelial cells allows functional analysis of the human tissue factor gene promoter. British Journal of Haematology, 1994, 88, 122-128.	2.5	33
106	High Purity Factor IX and Prothrombin Complex Concentrate (PCC): Pharmacokinetics and Evidence that Factor IXa Is the Thrombogenic Trigger in PCC. Thrombosis and Haemostasis, 1996, 76, 023-028.	3.4	33
107	Synthesis and characterization of wild-type and variant .gamma.-carboxyglutamic acid-containing domains of factor VII. Biochemistry, 1993, 32, 13949-13955.	2.5	32
108	The impact of sport on health status, psychological wellâ€being and physical performance of adults with haemophilia. Haemophilia, 2016, 22, 521-530.	2.1	32

#	Article	IF	Citations
109	Recent advances in developing specific therapies for haemophilia. British Journal of Haematology, 2018, 181, 161-172.	2.5	32
110	Expression of Hirudin Fusion Proteins in Mammalian Cells. Circulation, 1998, 98, 2744-2752.	1.6	31
111	The effect of liver disease on factors V, VIII and protein C. British Journal of Haematology, 1985, 61, 541-548.	2.5	30
112	von Willebrand factor and its disorders: An overview of recent molecular studies. Blood Reviews, 1989, 3, 251-262.	5.7	30
113	Detection of missense mutations by single-strand conformational polymorphism (SSCP) analysis in five dysfunctional variants of coagulation factor VII. Human Molecular Genetics, 1993, 2, 1355-1359.	2.9	30
114	Structural analysis of eight novel and 112 previously reported missense mutations in the interactive FXI mutation database reveals new insight on FXI deficiency. Thrombosis and Haemostasis, 2009, 102, 287-301.	3.4	30
115	Gene Therapy for Hemophilia. Hematology/Oncology Clinics of North America, 2017, 31, 853-868.	2.2	30
116	Analysis of the essential sequences of the factor VIII gene in twelve haemophilia A patients by single-stranded conformation polymorphism. Blood Coagulation and Fibrinolysis, 1994, 5, 257-264.	1.0	29
117	Severe perinatal thrombosis in double and triple heterozygous offspring of a family segregating two independent protein S mutations and a protein C mutation. Blood, 1996, 87, 3731-3737.	1.4	29
118	Optimizing warfarin reversal â€“ an exÂvivo study. Journal of Thrombosis and Haemostasis, 2009, 7, 1123-1127.	3.8	29
119	Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring. British Journal of Haematology, 2015, 168, 719-727.	2.5	29
120	Hyperviscosity Syndrome in IgA Multiple Myeloma. British Journal of Haematology, 1974, 27, 65-76.	2.5	26
121	A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency. British Journal of Haematology, 1993, 84, 290-300.	2.5	26
122	The haemophilia A mutation search test and resource site, home page of the factor VIII mutation database: HAMSTeRS. Nucleic Acids Research, 1996, 24, 100-102.	14.5	26
123	Â1-antitrypsin Pittsburgh in a family with bleeding tendency. Haematologica, 2009, 94, 881-884.	3.5	26
124	Albinism with haemorrhagic diathesis: Hermansky-Pudlak syndrome.. British Journal of Ophthalmology, 1985, 69, 904-908.	3.9	25
125	Factor VIII Ise (R2159C) in a Patient with Mild Hemophilia A, an Abnormal Factor VIII with Retention of Function but Modification of C2 Epitopes. Thrombosis and Haemostasis, 1997, 77, 0862-0867.	3.4	25
126	Mutations in haemophilia A. British Journal of Haematology, 1993, 83, 450-458.	2.5	23

#	Article	IF	Citations
127	The varieties of von Willebrand's disease. International Journal of Laboratory Hematology, 2008, 6, 307-323.	0.2	22
128	A common ancestral glycoprotein (GP) 9 1828A>G (Asn45Ser) gene mutation occurring in European families from Australia and Northern Europe with Bernard-Soulier syndrome (BSS). Thrombosis and Haemostasis, 2005, 94, 599-605.	3.4	21
129	CRM+haemophilia A due to a missense mutation (372â†'Cys) at the internal heavy chain thrombin cleavage site. British Journal of Haematology, 1990, 75, 73-77.	2.5	20
130	Coagulation Factor VII Gln100 â†' Arg. Journal of Biological Chemistry, 1998, 273, 8516-8521.	3.4	20
131	Postinjury vascular intimal hyperplasia in mice is completely inhibited by CD34+ bone marrow-derived progenitor cells expressing membrane-tethered anticoagulant fusion proteins. Journal of Thrombosis and Haemostasis, 2006, 4, 2191-2198.	3.8	19
132	Gene therapy for haemophilia B. Haemophilia, 2012, 18, 13-17.	2.1	19
133	Human Tissue Factor Pathway Inhibitor Fused to CD4 Binds both FXa and TF/FVIIa at the Cell Surface. Thrombosis and Haemostasis, 1997, 78, 1488-1494.	3.4	19
134	Early Clinical Trial Results Following Administration of a Low Dose of a Novel Self Complementary Adeno-Associated Viral Vector Encoding Human Factor IX In Two Subjects with Severe Hemophilia B. Blood, 2010, 116, 248-248.	1.4	19
135	Studies on immunological assay of vitamin K dependent factors. British Journal of Haematology, 1986, 62, 183-193.	2.5	18
136	Haemophilia A: carrier detection and prenatal diagnosis by linkage analysis using DNA polymorphism.. Journal of Clinical Pathology, 1987, 40, 971-977.	2.0	18
137	Symptomatic type II protein C deficiency caused by a missense mutation (Gly 381 â†' Ser) in the substrate-binding pocket. British Journal of Haematology, 1993, 84, 285-289.	2.5	18
138	Thrombophilla: a new factor emerges from the mists. Lancet, The, 1993, 342, 1501-1502.	13.7	17
139	Human thrombin and FXa mediate porcine endothelial cell activation; modulation by expression of TFPI-CD4 and hirudin-CD4 fusion proteins. Xenotransplantation, 2001, 8, 258-265.	2.8	17
140	Analysis of the consequences of premature termination codons within factor VIII coding sequences. Journal of Thrombosis and Haemostasis, 2003, 1, 139-146.	3.8	17
141	Factor VIIa and the extracellular domains of human tissue factor form a compact complex: A study by X-ray and neutron solution scattering. FEBS Letters, 1995, 374, 141-146.	2.8	16
142	Use of a non-depleting anti-CD4 antibody to modulate the immune response to coagulation factors VIII and IX. British Journal of Haematology, 2002, 118, 839-842.	2.5	16
143	Endogenous heparinoids contribute to coagulopathy in patients with liver disease. Journal of Hepatology, 2008, 48, 371-372.	3.7	16
144	Tissue Localization and Synthesis of Factor-VIII-Related Antigen in the Human Foetus. British Journal of Haematology, 1974, 26, 669-677.	2.5	14

#	Article	IF	Citations
145	Structural requirements for the interaction between tissue factor and factor VII: characterization of chymotrypsin-derived tissue factor polypeptides. Biochemical Journal, 1993, 292, 7-12.	3.7	14
146	The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding. Thrombosis and Haemostasis, 1992, 68, 464-469.	3.4	14
147	Thrombophilia: the new factor is old factor V. Lancet, The, 1994, 343, 1515-1516.	13.7	13
148	A Single Intravenous Infusion of FLT180a Results in Factor IX Activity Levels of More Than 40% and Has the Potential to Provide a Functional Cure for Patients with Haemophilia B. Blood, 2018, 132, 631-631.	1.4	13
149	Identification of six functional clotting factor VIII:C epitopes by analysis of cross-reactive public idiotypes in murine monoclonal VIII:C inhibitors. Thrombosis Research, 1987, 45, 527-536.	1.7	12
150	INCREASE OF ACTIVATED FACTOR VIIA AND HAEMOSTATIC MOLECULAR MARKERS IN JUVENILE CHRONIC ARTHRITIS. Rheumatology, 1995, 34, 466-469.	1.9	12
151	Global coagulation assays in hemophilia A: A comparison to conventional assays. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 298-308.	2.3	12
152	Reactions to low-molecular-weight porcine factor VIII concentrates.. BMJ: British Medical Journal, 1981, 283, 381-382.	2.3	11
153	Characterisation of blood coagulation factor XIT475I. Thrombosis and Haemostasis, 2005, 93, 1082-1088.	3.4	11
154	Production of factor VIII deficient plasma by immunodepletion using three monoclonal antibodies. British Journal of Haematology, 1987, 66, 497-502.	2.5	10
155	Crystallization and Preliminary X-ray Analysis of Human Tissue Factor Extracellular Domain. Journal of Molecular Biology, 1993, 234, 1263-1265.	4.2	10
156	An Alloantibody Recognizing the FVIII A1 Domain in a Patient with CRM Reduced Haemophilia A due to Deletion of a Large Portion of the A1 Domain DNA Sequence. Thrombosis and Haemostasis, 2000, 84, 442-448.	3.4	10
157	Characterisation of lymphocyte responses to Ca2+ in Scott syndrome. Thrombosis and Haemostasis, 2004, 91, 412-415.	3.4	10
158	Morphological and functional disturbances of platelets induced by cryopreservation.. Journal of Clinical Pathology, 1982, 35, 870-874.	2.0	9
159	Monoclonal antibodies to human factor VII: a one step immunoradiometric assay for VII:Ag.. Journal of Clinical Pathology, 1988, 41, 337-341.	2.0	9
160	Factor VII_{Shinj}_o: A Dysfunctional Factor VII Variant Homozygous for the Substitution Gln for Arg at Position 79. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1995, 25, 89-97.	0.3	9
161	Factor VIII gene analysis in Japanese CRM-positive and CRM-reduced haemophilia A patients by single-strand conformation polymorphism. British Journal of Haematology, 1997, 98, 901-906.	2.5	9
162	Gene therapy for the haemophilias. Haemophilia, 2000, 6, 115-119.	2.1	9

#	Article	IF	Citations
163	Two novel mutations in severe factor VII deficiency. British Journal of Haematology, 2004, 126, 105-110.	2.5	9
164	Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing. Thrombosis Research, 2007, 120, 135-139.	1.7	9
165	Genetics of haemostasis. Haemophilia, 2012, 18, 73-80.	2.1	9
166	Interaction Between the a3 Region of Factor VIII and the TILâ€™Eâ€™ Domains of the von Willebrand Factor. Biophysical Journal, 2019, 117, 479-489.	0.5	9
167	Disappearance of Antibodies to Factor VIII in a Patient with Acquired Haemophilia and Carcinoma of the Pancreas During Cytotoxic Therapy with Fluorouracil and CCNU. Thrombosis and Haemostasis, 1984, 52, 131-133.	3.4	9
168	Flip tip inversion and haemophilia A. Lancet, The, 1994, 343, 307-308.	13.7	8
169	Molecular genetics of familial venous thrombosis. British Medical Bulletin, 1994, 50, 833-850.	6.9	8
170	Mutation databases on the Web.. Journal of Medical Genetics, 1998, 35, 529-533.	3.2	8
171	RNA as drug and antidote. Nature, 2002, 419, 23-24.	27.8	8
172	Studies on immunological assay of vitamin K dependent factors... British Journal of Haematology, 1986, 62, 171-181.	2.5	7
173	In search of the eighth factor: a personal reminiscence. Journal of Thrombosis and Haemostasis, 2003, 1, 403-409.	3.8	7
174	Gene therapy for hemophilia?. Journal of Thrombosis and Haemostasis, 2005, 3, 1314-1314.	3.8	7
175	Detection of functional differences between different platelet membrane glycoprotein IbÂ variable number tandem repeat and Kozak genotypes as shown by the PFA-100 system. Heart, 2006, 92, 676-678.	2.9	7
176	Purification and characterization of factor VII 304-Gln: a variant molecule with reduced activity isolated from a clinically unaffected male. Blood, 1991, 78, 132-140.	1.4	7
177	ENDOTHELIAL CELLS AND FACTOR-VIII-RELATED PROTEIN. Lancet, The, 1976, 307, 46.	13.7	6
178	Detachment of Endothelial Cells by Polymorphonuclear Leukocytesin Vitro: Potentiation by Antibody Coating and Prevention by Inflammatory Exudate. Journal of Periodontology, 1981, 52, 668-672.	3.4	6
179	The effect of an acute phase reaction and BCBG innoculation on factor VIII in the guinea-pig. Thrombosis Research, 1985, 40, 445-451.	1.7	6
180	Axillary vein thrombosis in adolescent onset systemic sclerosis.. Annals of the Rheumatic Diseases, 1990, 49, 557-559.	0.9	6

#	Article	IF	Citations
181	A Standard Nomenclature for Factor VIII and Factor IX Gene Mutations and Associated Amino Acid Alterations. Thrombosis and Haemostasis, 1994, 72, 475-476.	3.4	6
182	10 Myeloproliferative and metabolic causes. Best Practice and Research: Clinical Haematology, 1994, 7, 591-635.	1.1	6
183	Inherited thrombophilias. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 375-378.	0.5	6
184	Crystallization and Preliminary X-Ray Analysis of Active Site-Inhibited Human Coagulation Factor VIIa (des-Gla). Journal of Structural Biology, 1999, 125, 90-93.	2.8	6
185	17 Levonorgestrel-releasing intrauterine system for the management of menorrhagia in women with inherited bleeding disorders: Long term follow-up. Thrombosis Research, 2007, 119, S101.	1.7	6
186	Therapeutic shoulder arthroscopy in patients with clotting disorders. Haemophilia, 2008, 14, 859-861.	2.1	6
187	Human Congenital Diseases with Mixed Modes of Inheritance Have a Shortage of Recessive Disease. A Demographic Scenario?. Annals of Human Genetics, 2011, 75, 688-693.	0.8	6
188	First steps in the standardization of immunoglobulin IgG myeloperoxidaseâ€antiâ€neutrophil cytoplasmic antibody measurements. Clinical and Experimental Immunology, 2016, 183, 193-205.	2.6	6
189	Factor VIII: the protein, cloning its gene, synthetic factor and now â€“ 35Âyears later â€“ gene therapy; what happened in between?. British Journal of Haematology, 2020, 189, 400-407.	2.5	6
190	Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor XI and Detection of Factor XI in Hep G2 Cell Conditioned Medium. Thrombosis and Haemostasis, 1990, 63, 417-423.	3.4	6
191	Immunologic studies of factor VIII coagulant activity (VIII:C) 2. Factor VIII in selected vertebrates. Thrombosis Research, 1982, 25, 423-431.	1.7	5
192	Inherited Bleeding Disorders. International Anesthesiology Clinics, 1985, 23, 61-72.	0.8	5
193	Response to desmopressin in type IID von Willebrand's disease. International Journal of Laboratory Hematology, 1989, 11, 189-197.	0.2	5
194	Stable recombinant expression and characterization of the two haemophilic factor VIII variants C329S (CRMâˆ) and G1948D (CRMr). British Journal of Haematology, 2001, 113, 604-615.	2.5	5
195	Anticoagulation after liver transplantation: a retrospective audit and caseâ€control study. Blood Coagulation and Fibrinolysis, 2009, 20, 615-618.	1.0	5
196	Molecular Biological Aspects of Inhibitor Development. Vox Sanguinis, 1999, 77, 13-16.	1.5	5
197	Lipogranuloma of the breast due to phenothiazine therapy. British Journal of Surgery, 2005, 57, 76-79.	0.3	4
198	Factor VIII: purer is not necessarily better. Blood, 2006, 107, 4-5.	1.4	4

#	Article	IF	Citations
199	In search of the source of factor VIII. Blood, 2014, 123, 3691-3691.	1.4	4
200	Stable High Level Coagulation Factor VIII Expression In Vivo Following Gene Transfer Using a Novel Expression Cassette Encoding a More Potent FVIII Variant. Blood, 2010, 116, 250-250.	1.4	4
201	Mutations of factor VIII cleavage sites in hemophilia A. Blood, 1988, 72, 1022-1028.	1.4	4
202	A monoclonal antibody based immunoradiometric assay for von willebrand factor: Survey of a large patient group. Thrombosis Research, 1987, 45, 101-108.	1.7	3
203	Monoclonal antibodies to human factor VII: production of immunodepleted plasma for VII:C assays.. Journal of Clinical Pathology, 1988, 41, 342-345.	2.0	3
204	O-132. Computerized thromboelastographic parameters amongst women with recurrent miscarriageâ€"evidence for a pro-thrombotic state. Human Reproduction, 1999, 14, 73-73.	0.9	3
205	Genetic aspects and research development in haemostasis. Haemophilia, 2008, 14, 113-118.	2.1	3
206	Purified factor VIII. BMJ: British Medical Journal, 1995, 311, 465-466.	2.3	3
207	Studies on immunological assay of vitamin-K dependent factors... British Journal of Haematology, 1986, 62, 513-524.	2.5	2
208	Flipping the tip of the X. Nature Genetics, 1993, 5, 209-209.	21.4	2
209	The Tissue Factor-Factor VII Complex: Recent Advances towards Elucidating the Structure and Function of the Initiator of Haemostasis. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 20-24.	0.3	2
210	Genetic and Laboratory Diagnosis. , 0, , 90-98.		2
211	Haemophilic pseudotumour of the carotid artery. Vascular Medicine, 2012, 17, 193-194.	1.5	2
212	Platelets are a safe way to deliver factor VIII. After 13 years of preclinical research it is now time for a clinical trial. Journal of Thrombosis and Haemostasis, 2017, 15, 96-97.	3.8	2
213	Cloned Factor VIII and the Molecular Genetics of Hemophilia. Cold Spring Harbor Symposia on Quantitative Biology, 1986, 51, 365-369.	1.1	2
214	Stable Factor IX Activity Following AAV-Mediated Gene Transfer in Patients with Severe Hemophilia B. Blood, 2012, 120, 752-752.	1.4	2
215	Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood, 1993, 81, 2339-2347.	1.4	2
216	Detection and characterization of seven novel protein S (PROS) gene lesions: evaluation of reverse transcript-polymerase chain reaction as a mutation screening strategy. Blood, 1995, 86, 2632-2641.	1.4	2

#	Article	IF	Citations
217	Regulated endothelial cell expression of novel anticoagulants: a strategy for the prevention and therapy of intravascular thrombosis. Transplantation Proceedings, 2000, 32, 971.	0.6	1
218	Consideration of platelet function disorders in patients with reduced VWF levels. Haemophilia, 2008, 14, 1131-1132.	2.1	1
219	Killing 2 birds with 1 stone. Blood, 2008, 112, 2595-2595.	1.4	1
220	Far away and long ago. Journal of Thrombosis and Haemostasis, 2014, 12, 34-35.	3.8	1
221	Normal Haemostasis. , 0, , 783-807.		1
222	Assessing the Potential of Perinatal Gene Transfer Using Congenital Factor VII Deficiency as a Model System. Blood, 2010, 116, 247-247.	1.4	1
223	Surgery with Turoctocog Alfa: Efficacy and Safety in Bleeding Prevention During Surgical Procedures - Results From the guardianâ„¢ Trials.. Blood, 2012, 120, 2228-2228.	1.4	1
224	Ways to bypass a blocked tenase complex. Thrombosis and Haemostasis, 2006, 95, 1-2.	3.4	1
225	Junior Hospital Doctors' Contract. BMJ: British Medical Journal, 1975, 1, 276-276.	2.3	0
226	Methylenetetrahydrofolate Reductase Mutation and Coronary Artery Disease. Circulation, 1998, 98, 2932-2935.	1.6	0
227	Haemophilia: does the future lie in replacement therapy or auto-supply?. Journal of the Royal Society of Medicine, 1998, 91, 506-506.	2.0	0
228	Commentary on book review: A History of Blood Coagulation. Haemophilia, 2002, 8, 62-62.	2.1	0
229	35. Downregulation of Immune Responses Induced by Oral DNA Administration. Molecular Therapy, 2004, 9, S15.	8.2	0
230	Factor VII and cardiovascular risk. Thrombosis and Haemostasis, 2005, 93, 189-189.	3.4	0
231	P53 Menorrhagia in adolescents with inherited bleeding disorders. Thrombosis Research, 2009, 123, S155.	1.7	0
232	"Magic" mushrooms don't cause renal failure. BMJ, The, 2012, 345, e6893-e6893.	6.0	0
233	Cellular Immune Responses To Vector In a Gene Therapy Trial For Hemophilia B Using An AAV8 Self-Complementary Factor IX Vector. Blood, 2013, 122, 717-717.	1.4	0
234	Exclusion of the First EGF Domain of Factor VII by a Splice Site Mutation Causes Lethal Factor VII Deficiency. Blood, 1998, 92, 920-926.	1.4	0

#	Article	IF	Citations
235	REGULATED ENDOTHELIAL CELL EXPRESSION OF NOVEL MOLECULES WITH ANTICOAGULANT PROPERTIES: A STRATEGY FOR THE PREVENTION AND THERAPY OF VASCULAR REJECTION. Transplantation, 1999, 67, S117.	1.0	0
236	Miscellaneous Questions. , 0, , 206-206.		0